Li Ping, Zhang Ning, Ping Fen, Gao Yanfeng, Cao Lei
Department of Gerontology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.
Exp Ther Med. 2019 Sep;18(3):1831-1836. doi: 10.3892/etm.2019.7729. Epub 2019 Jul 3.
The lungs are one of the most common target organs of diabetic injury in patients with diabetes. Long non-coding RNA (lncRNA) smoke and cancer-associated lncRNA 1 (SCAL1), also known as lung cancer associated transcript 1 (LUCAT1), is known to have a pivotal role in lung cancer. The aim of the current study was to investigate the potential involvement of SCAL1 in diabetic lung disease. The expression levels of SCAL1 were determined by reverse transcription-quantitative PCR in serum samples from healthy controls (n=40), diabetic patients without lung disease (n=56) and diabetic patients with diabetic lung disease (n=44). Receiver operating characteristic analysis was used to evaluate the diagnostic value of serum SCAL1 in discriminating diabetic patients with diabetic lung disease from diabetic patients without lung disease and healthy controls. Pearson's correlation analysis was performed to examine the correlation between SCAL1 and inducible nitric oxide synthase (iNOS) mRNA expression levels in blood and lung tissue samples. Expression levels of iNOS and NO production following treatment with high (30 mM) glucose were examined by western blot analysis and NO assay, respectively. The expression levels of SCAL1 were significantly downregulated in diabetic patients with diabetic lung disease, and downregulated serum expression levels of SCAL1 effectively distinguished diabetic patients with diabetic lung disease from diabetic patients without lung disease and healthy controls. Treatment with high glucose significantly upregulated SCAL1 expression in normal lung cells. Furthermore, the overexpression of SCAL1 inhibited iNOS protein expression and reduced NO production in cells treated with high glucose. In conclusion, the current study demonstrated that lncRNA SCAL1 inhibits iNOS protein expression in lung cells under high-glucose conditions, which suggests that SCAL1 may have potential in the treatment of patients with diabetic lung disease.
肺是糖尿病患者中最常见的糖尿病损伤靶器官之一。长链非编码RNA（lncRNA）烟与癌症相关lncRNA 1（SCAL1），也称为肺癌相关转录本1（LUCAT1），已知在肺癌中起关键作用。本研究的目的是探讨SCAL1在糖尿病性肺病中的潜在作用。通过逆转录定量PCR测定健康对照者（n = 40）、无肺病的糖尿病患者（n = 56）和患有糖尿病性肺病的糖尿病患者（n = 44）血清样本中SCAL1的表达水平。采用受试者工作特征分析来评估血清SCAL1在区分患有糖尿病性肺病的糖尿病患者与无肺病的糖尿病患者及健康对照者方面的诊断价值。进行Pearson相关性分析以检验血液和肺组织样本中SCAL1与诱导型一氧化氮合酶（iNOS）mRNA表达水平之间的相关性。分别通过蛋白质免疫印迹分析和NO测定法检测高糖（30 mM）处理后iNOS的表达水平和NO生成量。患有糖尿病性肺病的糖尿病患者中SCAL1的表达水平显著下调，且血清中SCAL1表达水平的下调有效地将患有糖尿病性肺病与无肺病的糖尿病患者及健康对照者区分开来。高糖处理显著上调正常肺细胞中SCAL1的表达。此外，SCAL1的过表达抑制了高糖处理细胞中iNOS蛋白的表达并减少了NO的生成。总之，本研究表明lncRNA SCAL1在高糖条件下抑制肺细胞中iNOS蛋白的表达，这表明SCAL1在糖尿病性肺病患者的治疗中可能具有潜力。
